Economic Evaluation of Pharmacogenomic-Guided Warfarin Treatment for Elderly Croatian Atrial Fibrillation Patients with Ischemic Stroke
- 1 January 2015
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 16 (2) , 137-148
Abstract
Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation in Croatia is cost effective compared with non-PGx therapy. The time horizon of the model was set at 1 year. Our primary analysis indicates that 97.07% (95% CI: 94.08-99.34%) of patients belonging to the PGx-guided group have not had any major complications, compared with the control group (89.12%; 95% CI: 84.00-93.87%, p < 0.05). The total cost per patient was estimated at €538.7 (95% CI: €526.3-551.2) for the PGx-guided group versus €219.7 (95% CI: €137.9-304.2) for the control group. In terms of quality-adjusted life-years (QALYs) gained, total QALYs was estimated at 0.954 (95% CI: 0.943-0.964) and 0.944 (95% CI: 0.931-0.956) for the PGx-guided and the control groups, respectively. The true difference in QALYs was estimated at 0.01 (95% CI: 0.005-0.015) in favor of the PGx-guided group. The incremental cost-effectiveness ratio of the PGx-guided versus the control groups was estimated at €31,225/QALY. Overall, our data indicate that PGx-guided warfarin treatment may represent a cost-effective therapy option for the management of elderly patients with atrial fibrillation who developed ischemic stroke in Croatia.Keywords
Funding Information
- Golden Helix Foundation (GHF_EE1303)
- Genomic Medicine Working Group
This publication has 40 references indexed in Scilit:
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Increasing Prevalence of Atrial Fibrillation and Flutter in the United StatesThe American Journal of Cardiology, 2009
- Epidemiology of atrial fibrillationJournal of Interventional Cardiac Electrophysiology, 2009
- Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification schemeAmerican Heart Journal, 2008
- Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)European Heart Journal, 2007
- Quality of Life in Patients with Atrial Fibrillation: A Systematic ReviewThe American Journal of Medicine, 2006
- Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam studyEuropean Heart Journal, 2006
- Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary careHeart, 2005
- Lifetime Risk for Development of Atrial FibrillationCirculation, 2004
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001